Replacement therapy in haemophilia A
Haemophilia. 2022;1–9.
Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
TH Open 2022 Feb 3;6(1):e60-e69. doi: 10.1055/a-1760-0105. eCollection 2022 Jan.
Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice
Blood Advances 2021 Oct 26;5(20):4314-4325. doi: 10.1182/bloodadvances.2021005096.
Patient-reported outcomes in autosomal inherited bleeding disorders
Haemophilia. 2022;28:197–214
Persoonlijke Gezondheidsomgeving voor meer inzicht en regie
NVHP Faktor editie maart 2022 De volledige Faktor kan gelezen worden op de NVHP website
Hoe beïnvloedt de bloedvatwand de bloedstolling?
NVHP Faktor editie maart 2022 De volledige Faktor kan gelezen worden op de NVHP website
Trombocytopathie in Nederland
NVHP Faktor editie maart 2022 De volledige Faktor kan gelezen worden op de NVHP website
Emicizumab Dosing in Children and Adults with Hemophilia A
Thromb Haemost 2022;122:208–215
Is pharmacokinetic-guided dosing of desmopressin
10.1136/bmjopen-2021-049493
Outcome of surgical interventions and deliveries in patients with bleeding of unknown cause
Thromb Haemost 2021;121:1409–1416